Definium Therapeutics, Inc.
- DFTX · Nasdaq
- Medicinal Chemicals & Botanical Products
- New York, NY
- 105 employees
- CIK 0001813814
Updated from SEC filings through
Top things to know
Executives
- Robert Barrow Chief Executive Officer Form 4, September 29, 2026
- Brandi Roberts Chief Financial Officer Form 4, September 29, 2026
- Daniel Karlin Chief Medical Officer Form 4, September 29, 2026
- Mark Sullivan Chief Legal Officer Form 4, September 29, 2026
- Matthew T. Wiley Chief Commercial Officer Form 4, September 29, 2026
What leadership is saying
“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions”
Earnings press release (8-K Ex. 99.1), filed November 9, 2026
Definium Therapeutics, Inc. is a U.S. public company in medicinal chemicals & botanical products (SIC 2833), headquartered in New York, NY. It trades as DFTX on Nasdaq. It reported about 105 employees. Robert Barrow is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | Not on file | Not on file | Not on file | Not on file | Not on file |
| Operating income | -$166M 10-K, 2026-02-26 | -$104M 10-K, 2026-02-26 | -$93.9M 10-K, 2025-03-06 | -$66.3M 10-K, 2024-02-28 | -$93.9M 10-K, 2023-03-09 |
| SG&A | $48.6M 10-K, 2026-02-26 | $38.6M 10-K, 2026-02-26 | $41.7M 10-K, 2025-03-06 | $30.2M 10-K, 2024-02-28 | $59.1M 10-K, 2023-03-09 |
| Net income | -$184M 10-K, 2026-02-26 | -$109M 10-K, 2026-02-26 | -$95.7M 10-K, 2025-03-06 | -$56.8M 10-K, 2024-02-28 | -$93.0M 10-K, 2023-03-09 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Robert Barrow Chief Executive Officer at Definium Therapeutics | Chief Executive Officer | Form 4, September 29, 2026 |
| Brandi Roberts Chief Financial Officer & Board Member | Chief Financial Officer | Form 4, September 29, 2026 |
| Daniel Karlin | Chief Medical Officer | Form 4, September 29, 2026 |
| Mark Sullivan | Chief Legal Officer | Form 4, September 29, 2026 |
| Matthew T. Wiley | Chief Commercial Officer | Form 4, September 29, 2026 |
| Andreas Krebs | Director | 10-K, February 26, 2026 |
| Carol Vallone | Director | 10-K, February 26, 2026 |
| David Gryska | Director | 10-K, February 26, 2026 |
| Roger Adsett | Director | 10-K, February 26, 2026 |
| Roger Crystal | Director | 10-K, February 26, 2026 |
| Suzanne Bruhn | Director | 10-K, February 26, 2026 |
What Definium Therapeutics, Inc. does
We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health disorders.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 136.9 million (as of November 2, 2026) | 10-Q, November 9, 2026 |
|---|---|---|
| Public float | $488M (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 9, 2026 |
| Latest proxy statement | Meeting June 11, 2026 (filed April 27, 2026) | DEF 14A, April 27, 2026 |
| Auditor | Kpmg LLP (San Diego, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 25, 2026 | Daniel Karlin Chief Medical Officer | Sale | 10,853 | $397K | Form 4, September 29, 2026 |
| September 25, 2026 | Robert Barrow Chief Executive Officer | Sale | 31,550 | $1.2M | Form 4, September 29, 2026 |
| September 25, 2026 | Matthew T. Wiley Chief Commercial Officer | Sale | 3,097 | $113K | Form 4, September 29, 2026 |
| September 25, 2026 | Mark Sullivan Chief Legal Officer | Sale | 14,051 | $514K | Form 4, September 29, 2026 |
| September 25, 2026 | Brandi Roberts Chief Financial Officer | Sale | 3,377 | $123K | Form 4, September 29, 2026 |
| September 3, 2026 | Robert Barrow Chief Executive Officer | Sale | 19,023 | $722K | Form 4, September 4, 2026 |
| June 25, 2026 | Mark Sullivan Chief Legal Officer | Sale | 13,008 | $586K | Form 4, June 26, 2026 |
| June 25, 2026 | Daniel Karlin Chief Medical Officer | Sale | 10,035 | $452K | Form 4, June 26, 2026 |
Recent 8-K events
- 8-K filed 2026-11-09
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-09-14
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-09-08
- Item 8.01 Other events
- 8-K filed 2026-08-12
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-24
- Item 1.01 Entry into a material definitive agreement
- Item 8.01 Other events
- 8-K filed 2026-06-22
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-06-12
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-19
- Item 8.01 Other events
- 8-K filed 2026-05-12
- Item 8.01 Other events
Frequently asked questions about Definium Therapeutics, Inc.
- What does Definium Therapeutics, Inc. do?
- In its own words, from Item 1 of its 10-K: "We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health disorders."
- How many employees does Definium Therapeutics, Inc. have?
- About 105 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Definium Therapeutics, Inc.?
- Robert Barrow, Chief Executive Officer, as named in a 4 filed September 29, 2026.
- Who is the CFO of Definium Therapeutics, Inc.?
- Brandi Roberts, Chief Financial Officer, as named in a 4 filed September 29, 2026.
- Where is Definium Therapeutics, Inc. headquartered?
- New York, NY.
- What is Definium Therapeutics, Inc.'s stock ticker?
- DFTX on Nasdaq.
- What industry is Definium Therapeutics, Inc. in?
- Medicinal Chemicals & Botanical Products, SIC code 2833.
- What is Definium Therapeutics, Inc.'s website?
- definiumtx.com. Investor relations: https://ir.definiumtx.com.
- When does Definium Therapeutics, Inc. report earnings next?
- January 18, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Definium Therapeutics, Inc. a public company?
- Yes. Definium Therapeutics, Inc. files with the SEC under CIK 0001813814 and trades as DFTX.
- Who audits Definium Therapeutics, Inc.?
- Kpmg LLP, San Diego, California, as named in its latest annual report (10-K).
- How many shares of Definium Therapeutics, Inc. are outstanding?
- 136.9 million shares as of November 2, 2026, from its 10-Q filed November 9, 2026.
- What is Definium Therapeutics, Inc.'s public float?
- $488M as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Definium Therapeutics, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 9, 2026.
- When is Definium Therapeutics, Inc.'s annual shareholder meeting?
- June 11, 2026, per its proxy statement (DEF 14A) filed April 27, 2026.
- Have Definium Therapeutics, Inc. insiders traded stock recently?
- Since September 25, 2025, officers and directors reported 20 open-market sales worth about $7.4M and 0 purchases on Forms 4 and 5. The most recent: Daniel Karlin (Chief Medical Officer) sold 10,853 shares on September 25, 2026.